
‘Dancing molecules’ treatment receives FDA Orphan Drug Designation
“Dancing molecules,” the promising new treatment for acute spinal cord injuries developed by CRN director Samuel Stupp, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).
The FDA’s Orphan Drug program is designed to encourage and support the development of treatments for rare diseases or conditions. The designation’s benefits include financial incentives such as tax credits for clinical trials, exemption from user fees and up to seven years of market exclusivity after approval.